CLDN18 and gastric cancer: It is also verified that the CLDN18-ARHGAP fusion gene is an oncogenic driver in GC, and patients with CLDN18-ARHGAP fusion were associated with worse survival outcomes and chemotherapy resistance (Shu et al, 2018).